Abstract
Over 15 million patients with epilepsy worldwide do not respond to medical therapy and may benefit from surgical treatment. In focal epilepsy, surgical treatment requires complete removal or disconnection of the epileptogenic zone (EZ). However, despite detailed multimodal pre-operative assessment, surgical success rates vary and may be as low as 30% in the most challenging cases. Here we demonstrate that neural fragility, a dynamical networked-system biomarker of epileptogenicity, decreases following successful surgical resection. Moreover, neural fragility increases or remains constant when seizure-freedom is not achieved. We demonstrate this retrospectively in a virtual patient with epilepsy using the Virtual Brain neuroinformatics platform, and subsequently on six children with epilepsy with pre- and post-resection intra-operative recordings. Finally, we compare neural fragility as a putative biomarker of epileptogenicity against established spectral metrics, such as high frequency oscillations and find that neural fragility is a superior biomarker of epileptogenicity.
Competing Interest Statement
The authors declare the following competing interests: AL, PM and SVS have equity in a startup, Neurologic Solutions Co., related to epilepsy data analysis. All other authors report no conflict of interest.
Funding Statement
AL is supported by NIH T32 EB003383, the NSF GRFP (DGE-1746891), the ARCS Scholarship, Whitaker Fellowship and the Chateaubriand Fellowship. SVS is supported by NIH R21 NS103113,Maryland Innovation Initiative and the Burroughs Wellcome Fund CASI Award 1007274.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Decisions regarding the need for invasive monitoring and the placement of electrode arrays were made independently of this work and part of routine clinical care. All data were acquired with ethics approval from the Research Ethics Board (REB) at the Hospital of Sick Children. The acquisition of data for research purposes was completed with no impact on the clinical objectives of the patient stay.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Fixed graph in Figure 5, writing and shortened main portion of the text.
Data Availability
Due to the unique nature of the data from the hospital for Sick Children and HIPAA concerns, the dataset cannot be made publicly available. Instead the data is available upon request from the clinical co-authors. In addition, the TVB dataset used in simulations is accessible upon request from Marseille University.
